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ABSTRACT

A clinical decision report using:

Hals IK, Fiskvik Fleiner H, Reimers N, et al. Investigating optimal β-cell-preserving treatment in latent autoimmune diabetes in adults:
Results from a 21-month randomized trial. Diabetes Obes Metab. 2019;21(10):2219-2227. https://doi.org/10.1111/dom.13797
for a patient with an aversion to needles.
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Clinical-Social Context
Kathleen Jones (pseudonym) is a 34-year-old middle-class Caucasian female with recently confirmed latent
autoimmune diabetes in adults (LADA) who presented to the clinic to discuss medication options for her diabetes.
Her diagnosis was made after testing positive for GAD antibodies (GADAs) with a fasting C‐peptide of 0.8 nmol/L.
She also did not require insulin for at least 6 months after diagnosis. Due to her previous misdiagnosis of type 2
diabetes mellitus, she was on Metformin 1000 mg twice a day for the past 2 years. Despite complete adherence,
her most recent HbA1c is 9.8%, which has increased from her initial HbA1c of 8.9%. However, her diet consisted of
exclusively fast food with a moderate level of activity. Her BMI was 44 kg/m2. During this visit, we needed to
reconsider and decide on additional medications to achieve better glycemic control.
First, we discussed the pathophysiology of LADA, in that it is a subtype of type 1 diabetes mellitus, an autoimmune
disease, and not due to insulin resistance. We explained the body is attacking the β‐cells, which produce the
insulin, but at a slower rate than we would see in type 1 diabetes. Therefore, insulin would now be needed, so we
discussed the treatment option of replacing the insulin lost with an injection. The pharmacist demonstrated how
to give the injection and as Ms. Jones observed, she winced at the site of the needle. She took a minute to think
about what we had told her, but then admitted, she was apprehensive of needles. She went on to give the
example that she has avoided receiving the influenza vaccine since 2011 because she cannot even handle the
thought of it, let alone pricking herself for sugar checks or injecting herself multiple times a day. She additionally
expressed that her priority is her son, who is disabled and requires full care from her and explained that she does
not have the time to deal with the time-demanding activities of insulin administration and sugar checks. We
validated Ms. Jones concerns and expressed our understanding of her situation. Ms. Jones then asked, “Is there
anything that I can take by mouth instead that works just as well?”
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Clinical Question
Is there an oral hypoglycemic medication that is an appropriate substitution to insulin that offers the same glycemic control and
beta-cell preserving therapy in patients diagnosed with latent autoimmune diabetes in adults?

Research Article
Hals IK, Fiskvik Fleiner H, Reimers N, et al. Investigating optimal β-cell-preserving treatment in latent autoimmune diabetes in adults:
Results from a 21-month randomized trial. Diabetes Obes Metab. 2019;21(10):2219-2227. https://doi.org/10.1111/dom.13797 1

Description of Related Literature
A search for original studies regarding treatment of LADA was conducted on PubMed by searching the terms: (Latent Autoimmune
Diabetes in Adults) AND (treatment). This yielded 232 results, in which only randomized control studies and clinical trials that were
published within the past 10 years were chosen yielding 11 articles. Of these, only 6 studies were selected because they addressed
treatment options and their ability to achieve glycemic control and/or preserve β‐cell function.
Pozzilli et. al. performed a post-hoc analysis from three randomized studies that was part of the dulaglutide clinical development
program in type 2 diabetes but included patients positive for glutamic acid decarboxylase (GAD) antibodies, the most sensitive
marker for LADA. By measuring HbA1c, this study evaluated the effect of dulaglutide in GADA-positive LADA versus GAD-negative
type 2 diabetes patients. Although, it was concluded that dulaglutide was effective in reducing HbA1c in LADA patients, this study
was excluded because dulaglutide is only available in an injectable form. 2
In the Johansen study, an exploratory analysis was done from a trial with 1,519 patients diagnosed with type 2 diabetes and HbA1c
of 6.5–10.0% on metformin. They were randomized to linagliptin 5 mg daily or glimepiride (sulfonylurea) 1−4 mg for 2 years. By
measuring multiple autoantibodies, they classified patients with LADA if positive for one or more autoantibody. The study failed to
show a significant decline in C-peptide levels and HbA1c with linagliptin compared to glimepiride. Although this study was
randomized with a large sample size, it was excluded due to a lack of placebo, the use of a second line agent as a comparator, and
the mean age of the study participants (ages 59-68).3 Furthermore, sulfonylureas have been shown to accelerate β‐cell deficiency in
type 2 diabetes in the long-term and to exert β‐cell toxicity in vitro, so the comparison drug was inferior to the current standard
treatment.4,5
In the Buzzetti study, a post hoc analysis was conducted from five trials, with 2709 participants from two studies of saxagliptin as
monotherapy, one study of saxagliptin as add‐on therapy to metformin, glyburide, or a thiazolidinedione. It also evaluated different
dosages of saxagliptin. Although it concluded that saxagliptin improves glycemic control, this study was excluded because it used
p < 0.1 as statistically significant and missing data were imputed using the last observation carried forward, decreasing the strength
of the evidence and validity of the study.6
Three of the studies selected focused their research on the dipeptidyl peptidase 4 inhibitor (DPP-4), sitagliptin with insulin as the
compared conventional treatment. The Zhao et. al. study is an open-label, randomized-controlled study with 15 participants
receiving insulin therapy and sitagliptin and the other 15 participants receiving insulin without sitagliptin for 12 months. The study
found that β-cell function was better maintained using sitagliptin compared to insulin alone. However, the study was limited
because it was only in Chinese populations; therefore, the treatment may not apply as well in individuals of non-Asian backgrounds.
Also, it was excluded because it had a very low power with only 15 patients in each of the treatment arms, the study was open label,
decreasing the validity of the study, and that both treatment arms included injectables. 7 The Wang et. al. study was also a one year
open‐label randomized controlled trial, but the primary emphasis was on the mechanism of how sitagliptin improves glycemic
control and β‐cell function by studying T-lymphocytes and relevant transcription factors. Although this study concluded that
sitagliptin altered the phenotype of T cells and improved glycemic control in LADA patients, it was excluded because the study was
open label, both treatment arms included an injectable, and it was done in an exclusively Chinese population.8
Ultimately, the Hals et. al. study was the most ideal choice for the critical review in the context of Ms. Jones. This randomized
controlled trial recruited GAD antibody-positive individuals. Glucagon‐stimulated C‐peptide tests (GSCTs), which evaluate β‐cell
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function, were performed at baseline, 3, 9, and 21 months. This study revealed that β‐cell preserving function was similar in insulin
and sitagliptin participants with LADA. Also, the results of this trial agree with the findings of the two other articles reviewed in this
process. The study has an appropriate sample size, randomized set-up, and focus on β‐cell preserving function using only an oral
medication, which made it relevant to Ms. Jones, therefore, this study was used to answer my clinical question.
Given the above literature, this body of evidence would be a Grade B strength of recommendation based on the SORT criteria. 9

Critical Appraisal
A non-blinded randomized control study was done to assess and compare the β‐cell preserving function of sitagliptin, a DPP-4
inhibitor, to insulin, the treatment of choice in patients with LADA. 10 According to the SORT criteria, it meets Level 2 evidence.9
Participants were recruited after testing positive for GAD antibody by their primary care physicians (PCP), health center screening
done by the investigators of this study, or through referral from PCPs. However, it is important to recognize that there are many
GAD antibody negative patients with LADA. Other antibodies that could be tested for are islet cell autoantibodies (ICA), tyrosine
phosphatase–related islet antigen 2 (IA-2), and insulin autoantibodies (IAA), however, these were not part of the studies recruitment
method, therefore, many GAD antibody negative LADA patients were not included in the study, which would have increased the
sample size.11
Participants that qualified for partaking in this trial had to meet several criteria: (1) ages 30 to 75 years, (2) positive for GAD
antibodies with <3 years of diagnosed diabetes, (3) no pharmacological treatment for diabetes except metformin, (4) no clinical
need for insulin, (5) HbA1c had to be at least 10% above the upper limit of normal (ULN) before treatment, or 5% above the ULN
when on treatment with metformin, but not exceeding 60% above the ULN at the time of randomization, and (6) fasting C‐peptide
≥0.3 nmol/L. Patients were excluded from the study if they had the following: (1) kidney failure (creatinine >150 μmol/L), (2)
proliferative retinopathy with or without sequelae, (3) myocardial infarction within the last 6 months, (4) unstable angina pectoris,
(5) serious chronic diseases, and (6) fertile women who planned to become pregnant during the study period.
Participants were started on metformin, if they were not already receiving it, with the dosage gradually being increased to 2
grams/day during the 3‐month run‐in period. Anthropometric measurements, blood pressure, relevant blood samples were taken
and measured at baseline. The primary outcome of the study, β‐cell function, was evaluated using glucagon‐stimulated C‐peptide
tests (GSCTs). Using a centralized randomization database, a total of 64 participants were randomized, non-blinded, with 32
individuals in the insulin arm and 32 individuals in the sitagliptin arm. The participants were also divided by age (≤53 years or >53
years) and body mass index (BMI; ≤26 kg/m2 or >26 kg/m2). Also, similar metabolic control in the two arms of the study was
attained because a large difference could potentially influence measures of β‐cell function. While there was no explanation for why
the study was not blinded, a potential explanation could be because the two treatments are delivered via different routes and
therefore, would be difficult to blind both treatment arms and the study’s staff. It is notable that this could potentially introduce
detection and performance bias through the study participants, data collectors, and data analysts. This could be minimized by
administering a placebo injection to the oral medication arm and placebo oral medication to the insulin arm.
Patients followed up with the research group after 3, 9, and 21 months. In Norway, 25 were followed up in Trondheim, one in
Namsos and five in Bergen. In Sweden, 32 were followed up in Stockholm and one in Malmö. The difference in follow up location
could potentially produce variability due to different equipment being used and those operating the equipment in each location.
After 21 months of intervention, it was ultimately revealed that there was no difference in fasting C‐peptide concentrations and
stimulated C‐peptide levels compared to baseline in both treatment arms. Also, the change of HbA1c levels was similar between
treatment arms. Therefore, it was concluded that β‐cell function was similarly affected in insulin and sitagliptin treated participants
with LADA. Additionally, the sitagliptin treatment group experienced greater weight loss with an average of 3.4 kg. While the insulin
arm had three participants that experienced hypoglycemia, there were no hypoglycemic events in the sitagliptin arm.
The mean age and BMI of the participants in the study was 53 years old and 27 kg/ m2 in both treatment arms, respectively.
Although Ms. Jones was younger than the mean age (34 years old) and her BMI was over the mean BMI (44 kg/ m2), she is still an
appropriate patient to apply this trial to as she meets all the inclusion criteria and does not meet the exclusion criteria. A limitation
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of the study is the lack of a control group. It would be beneficial to include another arm with participants treated with metformin
alone to assess the β‐cell preserving function to both treatment arms. Other limitations include the lack of uniformity in follow up
measurements due to different locations and lack of a blinded approach. Additionally, another limiting factor is that the study was
done in another country, where ethnicity and diet of participants differs from Ms. Jones.
One strength of the study is the appropriate sample size. A power calculation determined that 52 participants would be needed to
detect a 20% difference between treatments with a certainty of 80% at a P value of < 0.05. This study used 64 participants.
Additionally, the accumulated dropout was 9.4%, and while results of GSCTs from the dropouts at 3 to 9 months were carried
forward using the intention‐to‐treat principle, significance testing without these data did not change the study results. Other
strengths are the extended duration of the study and the randomized approach. 1

Clinical Application
Ms. Jones presented to the clinic to discuss treatment options for her recent diagnosis of LADA, but expressed
multiple concerns regarding the use of insulin injectables, the typical treatment. After extensive research, we
found our answer based on the article presented. This study concluded that β‐cell function was similarly affected
in insulin and sitagliptin treated participants with LADA. The clinical background of the participants in this study
closely match that of Ms. Jones, therefore, the study’s conclusions should also apply to Ms. Jones.
We spoke with Ms. Jones over the phone and explained to her that there is an oral hypoglycemic medication,
sitagliptin, that could work just as well as insulin in preserving her insulin producing cells. This would be added on
to her metformin, corresponding to the study. Furthermore, the importance of following up was explained to
assess how the medication is working for her and any side effects experienced, such as headache, throat irritation,
and upper respiratory tract infections. We came to an understanding that if proper glycemic control is not
achieved, then we will have to resort back to insulin injectables. She expressed understanding and was agreeable
with this plan. In addition to this, Ms. Jones was reminded of our extensive conversation regarding diet
modification and exercise. She was re-encouraged to commit to changes and explained that this will give her a
better chance at achieving glycemic control with her new treatment plan.

New Knowledge Related to Clinical Decision Science
Formulating a management and treatment plan for a patient should be collaborative and should take into account the medical and
social issues at hand. After witnessing Ms. Jones’s distress with insulin injections and listening to how she takes care of her disabled
son full-time, it became clear that imposing the injections would not be the best solution. This then led to the search for a
hypoglycemic medication that would serve as an appropriate substitute to insulin.
When calling the patient with the results of the literature review during clinic hours, it was apparent how grateful she was at both
her new treatment regimen and to hear from a provider. She discussed how clinic visits are time consuming, and this one phone call
trip saved her hours. Delivering follow up clinical care over the phone is a clinical practice that other doctors should emulate as it is
convenient, quick, and provides better access to patients.
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